Background. Autoregulation of GFR, i.e. maintenance of relative constancy of GFR despite variations in mean arterial pressure (MAP) >80 mmHg, is impaired in diabetic kidney disease; furthermore, some antihypertensive drugs may jeopardize autoregulation. The aim of our study was to establish if spironolactone affects the ability to autoregulate GFR. Methods. Sixteen hypertensive type 1 diabetic patients with persistent normoalbuminuria (presumed normal autoregulation) completed this randomized, double-masked, crossover trial. After a 4-week wash-out period, patients received spironolactone 25 mg o.d. and matched placebo for 4 weeks in random order. After each treatment period, the ability to autoregulate GFR was determined by measuring GFR ( 51 Cr-EDTA clearance) before (basal) and after acute blood pressure reduction by intravenous injection of clonidine. Results. During placebo, the mean (SE) basal GFR was 115 (5) ml/min/1.73 m 2 and the BP was 146 (4)/81 (2) mmHg corresponding to a MAP of 103 (2) mmHg. Spironolactone did not significantly reduce GFR or BP. Injection of clonidine induced a significant reduction in the MAP of 17 (2) and 19 (1) mmHg during placebo and spironolactone treatment, respectively, and an overall reduction in GFR of 11 and 15 ml/min/1.73 m 2 (both comparisons NS between treatment periods). Signs of impaired autoregulation were present in nine patients during placebo and in nine patients during spironolactone treatment. Relative changes in GFR on placebo treatment correlated with diabetes duration (R = 0.67, P < 0.01) but were not related to duration of hypertension, baseline BP, GFR, HbA1c or to changes in BP. Conclusion. Spironolactone did not change the overall ability to autoregulate GFR in 16 hypertensive type 1 diabetic patients with normoalbuminuria. Our data are suggestive that the ability to autoregulate GFR is gradually impaired with increasing diabetes duration, a phenomenon not previously described in normoalbuminuric patients.
Introduction
Autoregulation of glomerular filtration rate (GFR) designates the ability of the kidney to maintain a constant GFR over a wide range of renal perfusion pressures. In the normal kidney, autoregulatory mechanisms maintain a stable GFR despite changes in the mean arterial blood pressure (MAP) between 80 and 160 mmHg [1] . Impaired autoregulation of GFR implies disturbances in the downstream transmission of the systemic blood pressure (BP) into the glomerulus that lead to capillary hypertension or hypotension, depending on the level of systemic BP. Increased glomerular capillary pressure is an important factor in the development and progression of diabetic and non-diabetic glomerulopathies as demonstrated in experimental settings [2] .
We have previously shown that autoregulation of GFR is impaired or abolished in type 1 [3] and type 2 [4] diabetic patients with diabetic nephropathy. In addition, we investigated the effect of different antihypertensive drugs on renal autoregulation [5, 6] . The angiotensin II receptor antagonist, candesartan, was shown to reduce BP significantly without altering the preserved ability to autoregulate GFR in hypertensive type 2 diabetic patients without nephropathy [5] . In contrast, the calcium channel blocker isradipine induced a variable response ranging from no impact to impaired or abolished autoregulation of GFR [6] .
Treatment with the aldosterone antagonist spironolactone has recently been shown to reduce BP and albuminuria in type 1 [7] and type 2 [8, 9] diabetic patients with diabetic nephropathy. Aldosterone has been suggested to increase renal vascular resistance in the presence of endothelial dysfunction [10] . In experimental studies in isolated perfused afferent and efferent arterioles from rabbit kidneys, it has 3344 K. J. Schjoedt et al. been demonstrated that aldosterone induces vasoconstriction of both afferent and efferent arterioles with a higher sensitivity of the efferent arteriole [11] , i.e. blocking aldosterone with spironolactone may reduce intraglomerular pressure, but also has a potential of affecting the ability to autoregulate GFR by altering the vascular tone.
No information is available on the effects of spironolactone treatment on autoregulation of GFR in humans or animals. The aim of our study was to establish whether spironolactone affects the ability to autoregulate GFR in hypertensive type 1 diabetic patients.
Subjects and methods

Subjects
We enrolled a total of 17 patients from the outpatient clinic at Steno Diabetes Center. The patients were eligible for inclusion if they had type 1 diabetes, hypertension (>135/90 mmHg), persistent normoalbuminuria and normal kidney function (plasma creatinine <88 µmol/l in women and <100 µmol/l in men), age >18 and <70 years. The main exclusion criteria were plasma potassium >4.8 mmol/l, severe hypertension (>170/100), known kidney disease, previous stroke or transient cerebral ischaemia, chronic heart failure, myocardial infarction, unstable angina or coronary by-pass grafting within the last 3 months. Predefined criteria for termination from the study were BP >170/100, >35% increase in plasma creatinine, plasma potassium >5.5 on repeated measurements, symptomatic hypotension or systolic BP persistently <100 mmHg (except during clearance procedure).
Type 1 diabetic patients with hypertension but without nephropathy were selected for the present study to have a group of patients in need for antihypertensive treatment with normal kidney function and expected normal autoregulation during placebo treatment [4, 6] , in order to be able to identify a potentially interfering effect of spironolactone on the ability to autoregulate GFR.
Design
The study was a randomized, double-masked, crossover trial consisting of an initial 1-month wash-out period followed by two treatment periods, each lasting for 1 month. During the wash-out period, all antihypertensive treatments were withdrawn; however, some patients were put on slow-release furosemide in individual but fixed doses [median (range) 60 (0-120) mg daily] in order to prevent fluid retention, too high BP and hyperkalaemia during the study. After the wash-out period, patients were randomized to receive either spironolactone 25 mg once daily or matched placebo in the first treatment period followed by the other treatment in the second treatment period.
On the last day of each treatment period, the primary endpoint: ability to autoregulate GFR and the secondary endpoints: changes in blood pressure and urinary albumin excretion rate (UAER) were determined and blood samples were drawn for measuring components of the RAAS. For safety reasons, BP, plasma potassium, sodium and creatinine were determined 2 weeks after the beginning of each treatment period.
The study was performed according to the principles of the Declaration of Helsinki and approved by the ethical committee of Copenhagen County. The study was registered at clinicaltrials.gov, identification number: NCT00335413. All patients gave their informed consent. The study was monitored by the GCP unit at Copenhagen University Hospital Gentofte.
Laboratory procedures
The ability to autoregulate GFR was evaluated by determining GFR twice on the same day: first without clonidine and secondly after injection of clonidin 75 µg intravenously (clonidin induces a transient reduction in blood pressure, with no influence on renal plasma flow and GFR in healthy subjects and subjects with essential hypertension [3, 12, 13] ). Each measurement of GFR was performed during 4-h periods according to our standard procedure, after a single intravenous injection of 51 Cr-EDTA, by determining the radioactivity in venous blood samples taken 180, 200, 220 and 240 min after injection [14, 15] . The first GFR was determined using 1.5 MBq 51 Cr-EDTA and the second GFR by using 8.0 MBq 51 Cr-EDTA. To correct for background radioactivity, a venous blood sample was drawn before injection of 51 Cr-EDTA. Background radioactivity was subtracted from the individual radioactivity measured in both GFR measurements. Residual radioactivity from the first GFR measurement was calculated for each of the time points in the second GFR measurement and subtracted from the measured radioactivity at the time points 180, 200, 220 and 240 min after the second injection of 51 Cr-EDTA (8.0 MBq). The results were standardized for 1.73 m 2 body surface area, using the patient's surface area at the start of the study. Based on previous studies, impaired autoregulation was defined as a reduction in GFR >10% after clonidine injection [12, 13, 16] . Abolished autoregulation (complete pressure passive vasculature) was defined as MAP% ≤ GFR% in patients with impaired autoregulation as previously described [6] . 'Signs of impaired autoregulation' is used for all patients with a reduction in GFR >10%, including patients with a MAP < 80 mmHg (where normal autoregulation can not be expected). The patients were instructed to lie down during the whole procedure. All tests were carried out at Steno Diabetes Center under the observation of one doctor and one lab-technician.
Blood pressure and heart rate were measured by an automatic 24-h ambulatory blood pressure (ABP) device (Takeda TM2421; A & D Medical, Tokyo, Japan). BP was measured at baseline and every 15 min during each 4-h clearance procedure. Values were averaged for each hour before calculating the mean BP for each clearance procedure. The mean arterial blood pressure (MAP) was calculated as diastolic blood pressure plus one-third of the pulse pressure.
Urine was collected during each 4-h clearance period and urinary excretion of albumin was determined for each clearance period (Turbidimetry, Hitachi 912 system; Roche Diagnostics, Mannheim, Germany).
From venous samples, haemoglobin, HbA 1c and plasma potassium, sodium, creatinine and cholesterol concentrations were determined using standard techniques [17] . Blood samples for plasma renin activity and aldosterone concentrations were taken after 30 min of supine rest, i.e. 30 min after initiation of each clearance procedure. Plasma renin activity was measured by a method, based on determining by radioimmunoassay, the amount of angiotensin I generated, as previously described [18] . Plasma aldosterone was measured using a commercially available radioimmunoassay (Coat-a-Count, Diagnostic Products Corporation, Los Angeles, CA, USA).
Statistics
Normally distributed variables were expressed as means ± SD (baseline) and means ± SEM. Changes in variables between visits were expressed as means with 95% CI. UAER, plasma renin activity and plasma aldosterone were logarithmically transformed before statistical analysis owing to their skewed distribution and were given as geometric means (95% CI). Changes in these variables were expressed in percent. All comparisons of normally or log normally distributed parameters were performed with a paired Student's t-test. The Mann-Whitney test was used for the comparison between groups (impaired versus normal autoregulation) due to n = 3 in one group. Data were tested for a period effect and a treatment-period interaction as described by Altman [19] .
Linear regression analysis was used to analyse for correlations between the relative change in the MAP and changes in GFR.
A P-value <0.05 was considered significant (two-tailed test). Data were evaluated using SPSS version 14.0 (SPSS, Chicago, IL, USA).
We previously evaluated the reproducibility of the GFR and UAER by measuring them twice during the same day (8:00 A.M. to 12:00 P.M. versus 12:30 P.M. to 4:30 P.M.) in 13 type 2 diabetic patients using exactly the same methods as described in the present study, but without clonidine. The mean coefficient of variation in GFR was 3.9%, compared with the mean day-to-day coefficient of variation in GFR of 4% in our laboratory. No systematic alterations were demonstrated in GFR or UAER, thus ruling out time-dependent changes within the period from 8:00 A.M. to 4:30 P.M. Furthermore, no difference was found in mean arterial blood pressure during the two GFR measurements.
For power calculation, we used a previous study of similar design evaluating autoregulation of GFR in 16 type 2 diabetic patients [6] . The mean change in GFR during placebo treatment was 3.7 ml/min (SD 4.5). On the basis of these data, a sample size calculation showed a necessary minimum of 16 patients to detect a 3.2 ml/min difference in the change in GFR between placebo and spironolactone treatment (α = 0.05, β = 0.80).
Results
A total of 17 patients were randomized in the study. One patient was excluded during the second treatment period (placebo period) due to an unacceptable increase in BP. Five patients received a fixed dose of slow-release furosemide (60-120 mg daily) throughout the study. The baseline characteristics for 16 patients completing the study are given in Table 1 .
Seven of 16 patients received spironolactone in the first treatment period. The patients took 97% (86-100) [median (range)] of study medication during the placebo period and 97% (87-100) during the spironolactone period. There were no signs of a period effect or treatment-period interaction in relation to GFR, MAP or UAER.
Spironolactone 25 mg daily did not significantly reduce GFR, BP or UAER compared to placebo treatment ( Table 2 ). The reduction in systolic BP of 5 (−1 to 11) mmHg during spironolactone treatment did not reach statistical significance (P = 0.11). Spironolactone induced an expected compensatory increase in plasma aldosterone from [geometric mean (95% CI)] 39 (26-61) pg/ml dur- Data are given as n, mean (SD) and median (range).
ing placebo treatment to 66 (48-91) pg/ml during spironolactone treatment (P < 0.01). There was a similar tendency for plasma renin activity to increase from 2.5 (1.7-3.5) ngAI/ml/h during placebo to 3.3 (2.1-4.6) ngAI/ml/h during spironolactone treatment. Overall, clonidine induced a mean reduction in GFR of 11 (95% CI: 5-17) and 15 (11) (12) (13) (14) (15) (16) (17) (18) (19) ml/min/1.73 m 2 during placebo and spironolactone treatment, respectively (Table 2) . Corresponding values for the MAP were 17 (13-21) and 19 (17-21) mmHg. There were no significant differences in changes in GFR, BP or UAER between placebo and spironolactone periods ( Table 2) .
The individual changes in GFR, blood pressure and UAER induced by intravenous injection of clonidine during placebo and spironolactone treatment are shown in Table 3 . Injection of clonidine induced a reduction in GFR >10% (our cut-off for normal autoregulation) in nine patients in the placebo period and in nine patients in the spironolactone period, of whom five patients had a reduction of >10% in both periods, as depicted in Table 3 . Abolished autoregulation (complete pressure passive vasculature) was present in four patients during placebo treatment and one patient during spironolactone treatment (Table 3) . GFR reduction >10% was explained by a clonidine-induced reduction in the MAP <80 mmHg in two patients during placebo and five patients during spironolactone treatment (Table 3) .
There was a significant correlation between diabetes duration and relative changes in GFR (R = 0.67, P < 0.01), i.e. a longer diabetes duration was associated with a larger clonidine-induced reduction in GFR (Figure 1) . The patients with impaired autoregulation in one or both periods (n = 13) had a significantly larger reduction in the MAP after clonidine injection compared to patients with normal GFR response in both periods (n = 3), [19 (15-23) versus 9 (−1-19), respectively, during placebo, P < 0.05, and 20 (18) (19) (20) (21) (22) ) versus 14 (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) , respectively, during spironolactone treatment, P < 0.05], but there was no linear correlation between relative or absolute changes in the MAP and GFR either during treatment with placebo or spironolactone. There was no statistically significant difference in age, gender, duration of hypertension or baseline BP or HbA1c between the two groups. There was a tendency for patients with impaired autoregulation to have higher plasma aldosterone levels and higher plasma renin activity at baseline than those with normal autoregulation [plasma aldosterone: 47 (30-72) and 19 (2-182), respectively, P = 0.09, and plasma renin activity: 2.8 (1.9-4.3) and 1.4 (1.2-1.5), respectively, P = 0.07]. In the placebo period, injection of clonidine induced a reduction in plasma aldosterone of 39% (3-53%), P = 0.03. This reduction in aldosterone was associated with the reduction in the MAP (R = 0.51, P = 0.04), but not with changes in GFR. A similar association was not found during spironolactone treatment. Changes in plasma renin activity were not associated with changes in the MAP or GFR. One patient reported mild headache during both treatment periods. No other adverse effects were reported. Except for the expected sleepiness, no adverse effects were observed after injection of clonidine.
Discussion
In our randomized, double-masked, crossover trial, a statistically significant difference in the ability to autoregulate GFR could not be detected between placebo and spironolactone treatment. Signs of impaired autoregulation ( GFR >10%) were present in nine patients during placebo and in nine patients during spironolactone treatment. Complete pressure-passive vasculature (i.e. GFR >10% and MAP% ≤ GFR%) was present in four patients during placebo and in one patient during spironolactone treatment. The reduction in GFR could be ascribed to a reduction in the MAP <80 mmHg in two patients during placebo and five patients during spironolactone treatment. Since preserved autoregulation can only be expected with a MAP >80 mmHg, actual impaired autoregulation was present in seven patients during placebo and four patients during spironolactone; i.e. spironolactone does not seem to impair the ability to autoregulate GFR in hypertensive type 1 diabetic patients.
Spironolactone did not significantly reduce BP, UAER or GFR compared to placebo in our study, although the lack of statistical significance for the reduction in systolic BP of 5 mmHg may simply reflect the lack of power since we did not record 24-h blood pressure as we did in our previous spironolactone studies. This is in contrast to studies in type 1 and type 2 diabetic patients with diabetic nephropathy where spironolactone 25 mg once daily on top of ongoing recommended antihypertensive treatment induced a reduction in BP of 6-8/3-4 mmHg and a 30% reduction in albuminuria [7, 8, 17] . The reduction in BP and albuminuria was associated with an initial reversible decline in GFR in our patients with diabetic nephropathy [7, 8] , as also reported in patients with chronic glomerulonephritis treated with spironolactone for 1 year [20] . The mechanism behind the reversible decline in GFR is unknown, but could potentially be due to (i) a spironolactone-induced impairment on the ability to autoregulate GFR, leaving the glomerulus vulnerable to systemic hypertension or hypotension; or (ii) a spironolactone-induced beneficial reduction in the intraglomerular pressure with preserved ability to autoregulate GFR. An initial rapid decline in GFR during spironolactone treatment has recently been suggested to be followed by a stabilization of kidney function [20] .
In the placebo period, injection of clonidine induced a significant reduction in plasma aldosterone of 39%, which was associated with the reduction in the MAP. This may reflect a clonidin-induced reduction in sympathetic augmented aldosterone release from the adrenal cortex as suggested from experimental studies [21] [22] [23] .
Autoregulation of GFR has previously been shown to be impaired or even abolished in type 1 and type 2 diabetic patients with diabetic nephropathy and in patients with non-diabetic nephropathies [3, 4, 16] . For the present study, we chose hypertensive patients without nephropathy to have a group of diabetic patients with expected preserved autoregulation during placebo treatment, in order to be able to identify a possible effect of spironolactone on the ability to autoregulate GFR. Surprisingly, however, signs of impaired autoregulation were present in nine patients during placebo treatment. Looking further into this unexpected observation, we found that impaired autoregulation may be present as a result of long-standing diabetes, i.e. relative changes in GFR after clonidine injection correlated positively with diabetes duration (Figure 1 ). This is consistent with the fact that fewer patients had impaired autoregulation in previous studies in hypertensive type 1 and type 2 diabetic patients without nephropathy [3] [4] [5] [6] . In these studies, the mean known diabetes duration was 7-14 years as compared to our patients with a mean diabetes duration of 27 years. In fact, all patients with impaired autoregulation in the present study except for one had a diabetes duration of >25 years. In accordance with our findings, it has recently been demonstrated that impaired dynamic cerebral autoregulation correlated closely with diabetes duration [24] , i.e. dynamic cerebral autoregulation was impaired in type 2 diabetic patients without manifest microvascular complications compared to healthy control subjects, with a further worsening in patients with type 2 diabetes and microvascular complications [24] . Altogether, it is suggested that long-standing diabetes per se can affect renal and cerebral autoregulation, although acute changes in blood glucose do not influence the ability to autoregulate GFR [25] or the dynamic cerebral autoregulatory capacity [26] . Age and duration of hypertension were not associated with the absence or presence of impaired autoregulation.
The impairment of renal autoregulation in our patients without diabetic nephropathy may be due to arteriolar hyalinosis, a structural damage which affects both the afferent and efferent arterioles in diabetic nephropathy and whose severity is associated with age, duration of diabetes and duration of hypertension [27, 28] . Since the biological age is ∼15 years higher than the chronological age in relation to vascular damage in diabetes [29] , our patients suffer from all three risk factors/markers, as mentioned above.
The effect of spironolactone on autoregulation of GFR in patients with overt diabetic nephropathy was not evaluated since GFR autoregulation is known to be impaired/abolished in these patients [3, 4] , and therefore, it would be impossible to demonstrate a detrimental effect on autoregulation in such patients. In fact, it would only be possible to evaluate whether spironolactone could restore autoregulation in type 1 diabetic patients with nephropathy. It was regarded as highly unlikely to demonstrate such an effect in a short-term study as patients with overt diabetic nephropathy have severe structural lesions such as arteriolar hyalinosis, which probably causes an irreversible impairment of kidney autoregulation [30] .
There are two primary mechanisms responsible for autoregulation of GFR: a myogenic reflex and the tubuloglomerular feedback (TGF) as reviewed by Palmer [31] and Loutzenhiser [32] . The myogenic reflex involves a direct vasoconstriction of the afferent arteriole when the vessel is presented to an increase in transmural pressure. TGF involves a flow-dependent signal that is sensed at the macula densa and alters tone in the adjacent segment of the afferent arteriole. In addition to being necessary for normal kidney function and volume homeostasis, renal autoregulation is responsible for protecting the kidney against the damaging effects of hypo-and hypertension [32] .
A dose of spironolactone 25 mg once daily was chosen since this dose has been shown to effectively reduce BP and albuminuria in type 1 and type 2 diabetic patients with diabetic nephropathy and cause only few adverse effects [7] [8] [9] 17] . Slow-release furosemide was allowed in individually fixed doses as supplementary treatment in order to avoid hyperkalaemia, oedema and an unacceptable increase in BP during the study. Long-term treatment with loop diuretics (as slow release furosemide) has no impact on autoregulation in humans [33] . Intravenous injection of clonidine was chosen for acute blood pressure lowering in the present study because it has no direct effect on renal vessels [12, 13, 34] . Considerable evidence indicates that the hypotensive effect of clonidine is exerted at alpha adrenoceptors in the medulla of the brain. It reduces sympathetic outflow from the brain, resulting in decreased heart rate and relaxation of capacitance vessels and consequently a reduction in cardiac output and blood pressure [35] . Intravenous injection of clonidine (150-300 µg) induces no significant change in renal plasma flow and GFR [3, 12, 13, 16] . Finally, we have successfully used clonidine in doses ranging from 75 to 300 µg in several previous trials with no adverse events [3] [4] [5] [6] 16, 25] .
Some limitations to our study that could confound our interpretations should be mentioned: (i) the clonidineinduced reduction in BP was larger than expected, resulting in a MAP <80 mmHg in six patients during one or both treatment periods. (ii) There is a partial mismatch regarding patients who have impaired autoregulation in the placebo period, compared to the spironolactone period. (iii) Finally, basal GFR varied more than expected between the placebo and spironolactone treatment periods in some patients (patients 1, 3, 8, 11, 12 and 16) . This was most likely due to intermittent hyperfiltration in these patients and was not reflected in plasma creatinine levels (max. ± 6 µmol/l, data not shown). Furthermore, it did not affect the individual order of magnitude of the clonidine-induced changes in GFR between placebo and spironolactone treatment periods, except for patient 12. However, we cannot rule out that the variation in basal GFR could confound our interpretations.
Our study was designed to evaluate whether spironolactone affects the ability to autoregulate GFR. Future studies should further explore the impact of spironolactone on renal haemodynamics by measuring renal plasma flow in parallel to GFR before and after administration of the drug, e.g. in resemblance to a study previously performed with the angiotensin II receptor blocker irbesartan [36] .
In conclusion, spironolactone did not change the overall ability to autoregulate GFR in 16 hypertensive type 1 diabetic patients with normoalbuminuria. Our data are suggestive that the ability to autoregulate GFR is gradually impaired with increasing diabetes duration, a phenomenon not previously described in normoalbuminuric patients.
